The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation

James Waxmonsky, William E. Pelham, Elizabeth Gnagy, Michael R. Cummings, Briannon O'Connor, Antara Majumdar, Jessica Verley, Martin T. Hoffman, Greta A. Massetti, Lisa Burrows-MacLean, Gregory A. Fabiano, Daniel A. Waschbusch, Anil Chacko, Frances W. Arnold, Kathryn S. Walker, Allison C. Garefino, Jessica A. Robb

Research output: Contribution to journalArticle

Abstract

Objectives: This study examines the tolerability and efficacy of methylphenidate (MPH) and behavior modification therapy (BMOD) in children with attention-deficity/hyperactivity disorder (ADHD) and severe mood dysregulation (SMD). Methods: Children (ages 5-12) from a summer program for ADHD were screened for SMD and additional manic-like symptoms using structured assessments and direct clinical interview with the Young Mania Rating Scale (YMRS). The SMD group was comprised of 33 subjects with SMD and elevated YMRS scores (mean = 23.7). They underwent weekly mood assessments plus the daily ADHD measures that are part of the program. The comparison group (n = 68) was comprised of the rest of the program participants. Using a crossover design, all subjects in both groups were treated with three varying intensities of BMOD (no, low, high) each lasting 3 weeks, with MPH dose (placebo, 0.15 mg/kg t.i.d., 0.3mg/kg t.i.d., and 0.6mg/kg t.i.d.) varying daily within each behavioral treatment. Results: Groups had comparable ADHD symptoms at baseline, with the SMD group manifesting more oppositional defiant disorder/conduct disorder (ODD/CD) symptoms (p < 0.001). Both groups showed robust improvement in externalizing symptoms (p < 0.001). There was no evidence of differential treatment efficacy or tolerability. Treatment produced a 34% reduction in YMRS ratings in SMD subjects (p - 0.001). However, they still exhibited elevated YMRS ratings, more ODD/CD symptoms (p < 0.001), and were more likely to remain significantly impaired at home than non-SMD subjects (p < 0.05). Conclusions: MPH and BMOD are tolerable and effective treatments for children with ADHD and SMD, but additional treatments may be needed to optimize their functioning.

Original languageEnglish (US)
Pages (from-to)573-588
Number of pages16
JournalJournal of Child and Adolescent Psychopharmacology
Volume18
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Methylphenidate
Behavior Therapy
Attention Deficit Disorder with Hyperactivity
Bipolar Disorder
Attention Deficit and Disruptive Behavior Disorders
Conduct Disorder
Mood Disorders
Therapeutics
Cross-Over Studies
Placebos
Interviews

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. / Waxmonsky, James; Pelham, William E.; Gnagy, Elizabeth; Cummings, Michael R.; O'Connor, Briannon; Majumdar, Antara; Verley, Jessica; Hoffman, Martin T.; Massetti, Greta A.; Burrows-MacLean, Lisa; Fabiano, Gregory A.; Waschbusch, Daniel A.; Chacko, Anil; Arnold, Frances W.; Walker, Kathryn S.; Garefino, Allison C.; Robb, Jessica A.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 18, No. 6, 01.12.2008, p. 573-588.

Research output: Contribution to journalArticle

Waxmonsky, J, Pelham, WE, Gnagy, E, Cummings, MR, O'Connor, B, Majumdar, A, Verley, J, Hoffman, MT, Massetti, GA, Burrows-MacLean, L, Fabiano, GA, Waschbusch, DA, Chacko, A, Arnold, FW, Walker, KS, Garefino, AC & Robb, JA 2008, 'The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation', Journal of Child and Adolescent Psychopharmacology, vol. 18, no. 6, pp. 573-588. https://doi.org/10.1089/cap.2008.065
Waxmonsky, James ; Pelham, William E. ; Gnagy, Elizabeth ; Cummings, Michael R. ; O'Connor, Briannon ; Majumdar, Antara ; Verley, Jessica ; Hoffman, Martin T. ; Massetti, Greta A. ; Burrows-MacLean, Lisa ; Fabiano, Gregory A. ; Waschbusch, Daniel A. ; Chacko, Anil ; Arnold, Frances W. ; Walker, Kathryn S. ; Garefino, Allison C. ; Robb, Jessica A. / The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. In: Journal of Child and Adolescent Psychopharmacology. 2008 ; Vol. 18, No. 6. pp. 573-588.
@article{f8fcb01a1e52444d8d87a5e404c1504c,
title = "The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation",
abstract = "Objectives: This study examines the tolerability and efficacy of methylphenidate (MPH) and behavior modification therapy (BMOD) in children with attention-deficity/hyperactivity disorder (ADHD) and severe mood dysregulation (SMD). Methods: Children (ages 5-12) from a summer program for ADHD were screened for SMD and additional manic-like symptoms using structured assessments and direct clinical interview with the Young Mania Rating Scale (YMRS). The SMD group was comprised of 33 subjects with SMD and elevated YMRS scores (mean = 23.7). They underwent weekly mood assessments plus the daily ADHD measures that are part of the program. The comparison group (n = 68) was comprised of the rest of the program participants. Using a crossover design, all subjects in both groups were treated with three varying intensities of BMOD (no, low, high) each lasting 3 weeks, with MPH dose (placebo, 0.15 mg/kg t.i.d., 0.3mg/kg t.i.d., and 0.6mg/kg t.i.d.) varying daily within each behavioral treatment. Results: Groups had comparable ADHD symptoms at baseline, with the SMD group manifesting more oppositional defiant disorder/conduct disorder (ODD/CD) symptoms (p < 0.001). Both groups showed robust improvement in externalizing symptoms (p < 0.001). There was no evidence of differential treatment efficacy or tolerability. Treatment produced a 34{\%} reduction in YMRS ratings in SMD subjects (p - 0.001). However, they still exhibited elevated YMRS ratings, more ODD/CD symptoms (p < 0.001), and were more likely to remain significantly impaired at home than non-SMD subjects (p < 0.05). Conclusions: MPH and BMOD are tolerable and effective treatments for children with ADHD and SMD, but additional treatments may be needed to optimize their functioning.",
author = "James Waxmonsky and Pelham, {William E.} and Elizabeth Gnagy and Cummings, {Michael R.} and Briannon O'Connor and Antara Majumdar and Jessica Verley and Hoffman, {Martin T.} and Massetti, {Greta A.} and Lisa Burrows-MacLean and Fabiano, {Gregory A.} and Waschbusch, {Daniel A.} and Anil Chacko and Arnold, {Frances W.} and Walker, {Kathryn S.} and Garefino, {Allison C.} and Robb, {Jessica A.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1089/cap.2008.065",
language = "English (US)",
volume = "18",
pages = "573--588",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation

AU - Waxmonsky, James

AU - Pelham, William E.

AU - Gnagy, Elizabeth

AU - Cummings, Michael R.

AU - O'Connor, Briannon

AU - Majumdar, Antara

AU - Verley, Jessica

AU - Hoffman, Martin T.

AU - Massetti, Greta A.

AU - Burrows-MacLean, Lisa

AU - Fabiano, Gregory A.

AU - Waschbusch, Daniel A.

AU - Chacko, Anil

AU - Arnold, Frances W.

AU - Walker, Kathryn S.

AU - Garefino, Allison C.

AU - Robb, Jessica A.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Objectives: This study examines the tolerability and efficacy of methylphenidate (MPH) and behavior modification therapy (BMOD) in children with attention-deficity/hyperactivity disorder (ADHD) and severe mood dysregulation (SMD). Methods: Children (ages 5-12) from a summer program for ADHD were screened for SMD and additional manic-like symptoms using structured assessments and direct clinical interview with the Young Mania Rating Scale (YMRS). The SMD group was comprised of 33 subjects with SMD and elevated YMRS scores (mean = 23.7). They underwent weekly mood assessments plus the daily ADHD measures that are part of the program. The comparison group (n = 68) was comprised of the rest of the program participants. Using a crossover design, all subjects in both groups were treated with three varying intensities of BMOD (no, low, high) each lasting 3 weeks, with MPH dose (placebo, 0.15 mg/kg t.i.d., 0.3mg/kg t.i.d., and 0.6mg/kg t.i.d.) varying daily within each behavioral treatment. Results: Groups had comparable ADHD symptoms at baseline, with the SMD group manifesting more oppositional defiant disorder/conduct disorder (ODD/CD) symptoms (p < 0.001). Both groups showed robust improvement in externalizing symptoms (p < 0.001). There was no evidence of differential treatment efficacy or tolerability. Treatment produced a 34% reduction in YMRS ratings in SMD subjects (p - 0.001). However, they still exhibited elevated YMRS ratings, more ODD/CD symptoms (p < 0.001), and were more likely to remain significantly impaired at home than non-SMD subjects (p < 0.05). Conclusions: MPH and BMOD are tolerable and effective treatments for children with ADHD and SMD, but additional treatments may be needed to optimize their functioning.

AB - Objectives: This study examines the tolerability and efficacy of methylphenidate (MPH) and behavior modification therapy (BMOD) in children with attention-deficity/hyperactivity disorder (ADHD) and severe mood dysregulation (SMD). Methods: Children (ages 5-12) from a summer program for ADHD were screened for SMD and additional manic-like symptoms using structured assessments and direct clinical interview with the Young Mania Rating Scale (YMRS). The SMD group was comprised of 33 subjects with SMD and elevated YMRS scores (mean = 23.7). They underwent weekly mood assessments plus the daily ADHD measures that are part of the program. The comparison group (n = 68) was comprised of the rest of the program participants. Using a crossover design, all subjects in both groups were treated with three varying intensities of BMOD (no, low, high) each lasting 3 weeks, with MPH dose (placebo, 0.15 mg/kg t.i.d., 0.3mg/kg t.i.d., and 0.6mg/kg t.i.d.) varying daily within each behavioral treatment. Results: Groups had comparable ADHD symptoms at baseline, with the SMD group manifesting more oppositional defiant disorder/conduct disorder (ODD/CD) symptoms (p < 0.001). Both groups showed robust improvement in externalizing symptoms (p < 0.001). There was no evidence of differential treatment efficacy or tolerability. Treatment produced a 34% reduction in YMRS ratings in SMD subjects (p - 0.001). However, they still exhibited elevated YMRS ratings, more ODD/CD symptoms (p < 0.001), and were more likely to remain significantly impaired at home than non-SMD subjects (p < 0.05). Conclusions: MPH and BMOD are tolerable and effective treatments for children with ADHD and SMD, but additional treatments may be needed to optimize their functioning.

UR - http://www.scopus.com/inward/record.url?scp=58149125148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149125148&partnerID=8YFLogxK

U2 - 10.1089/cap.2008.065

DO - 10.1089/cap.2008.065

M3 - Article

C2 - 19108662

AN - SCOPUS:58149125148

VL - 18

SP - 573

EP - 588

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 6

ER -